XenoGesis
XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.
It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically,XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.
To read the latest XenoGesis newsletter click here.
XenoGesis Company Video 2017 from XenoGesis Limited on Vimeo.
Contact XenoGesis via their website
News Archive
16/12/2020 Xenogesis reflects: 2020, a year to remember...more
21/09/2020 XenoGesis acquired by Sygnature Discovery...more
21/09/2020 XenoGesis Guest blog by Rob Harris: A new trick for an old dog...more
16/09/2020 XenoGesis partners with Quay Pharma...more
15/09/2020 XenoGesis shortlisted in Sunday Times Ones to Watch...more
09/09/2020 DIT highlights XenoGesis: A winning strategy for international success...more
08/09/2020 Spotlight on Formulation − XenoGesis interviews Rob Harris...more
27/06/2020 See XenoGesis in the MDC Drug Discovery Webinar Series available online...more
03/06/2020 LUNAC Therapeutics selects XenoGesis as strategic drug discovery partner...more
22/05/2020 XenoGesis BD Director joins University of Oxford′s Experts in Residence...more
05/05/2020 Xenogesis joins forces with Other Expert CROs during the pandemic...more
21/04/2020 XenoGesis receives Queen’s Award for Enterprise for export growth...more
14/04/2020 XenoGesis supports Sitryx in solving complex PK issues...more
14/04/2020 XenGesis to speak at Medicines Discovery Catapult webinars...more
26/02/2020 Xenogesis Joins Forces with Catalent to Deliver PBPK/DMPK Webinar...more
03/02/2020 XenoGesis shortlisted as national finalist for Export Achievement...more
29/01/2020 XenoGesis expands bioanalytical capacity with 2 new mass specs...more
18/12/2019 Rachel Hemsley celebrates two years at XenoGesis...more
06/12/2019 XenoGesis takes home Medlink Export Achievement Award...more
14/10/2019 Xenogesis CEO shortlisted in IoD Director of the Year Awards ...more
23/09/2019 Xenogesis partner TropIQ's malaria candidate drug offers considerable potential...more
18/09/2019 XenoGesis bolsters profile and relationships in the US West Coast region...more
23/06/2019 XenoGesis Founder and CEO, Richard Weaver named Director of the Year ...more
01/05/2019 BioPartner Appoints Rachel Hemsley of Xenogesis to its Advisory Board...more
26/04/2019 Medicines Discovery Catapult launches 22 UK CRO partnerships including Xenogesis...more
01/10/2018 XenoGesis opens new laboratories and offices at BioCity's Discovery Building...more
13/09/2018 XenoGesis to attend DMDG...more
30/07/2018 Xenogesis' Richard Weaver to co-chair Pharma Integrates conference...more
11/07/2018 CellCentric CCS1477 enters trial following DMPK support from XenoGesis...more
20/05/2018 XenoGesis to expand into Discovery Building...more
16/05/2018 Xenogesis announces BioAscent alliance for integrated services...more
27/03/2018 XenoGesis and Sygnature Discovery hosted DMPK-DMDG meeting...more
18/03/2018 XenoGesis launches new ‘Metabolism-inform’ service...more
16/03/2018 XenoGesis experiences continued growth...more
07/02/2018 XenoGesis moves into BioHub as expansion plans continue...more
27/11/2017 XenoGesis has appointed Dr Rachel Hemsley as global head of business development...more
09/11/2017 XenoGesis and Juniper Pharma Services strengthen alliance with investment in GastroPlus...more
17/10/2017 XenoGesis and Juniper Pharma Services strengthen alliance with investment in GastroPlus...more
28/09/2017 Meet XenoGesis at several forthcoming events...more
17/08/2017 XenoGesis shortlisted as Finalist at 2017 OBN Awards...more
13/08/2017 XenoGesis and Juniper Pharma Services to deliver joint case study at BOS 2017...more
27/06/2017 Meet XenoGesis and Juniper Pharma Services at BOS Basel 2017...more
14/06/2017 XenoGesis Reports Third Year of Export Growth...more
05/06/2017 Sareum notes Sierra Oncology announcement of Chk1 inhibitor SRA737 encouraging...more
28/04/2017 XenoGesis to join panel at ON Helix Welcome Reception...more
31/03/2017 Latest news from Xenogesis...more
26/03/2017 XenoGesis through to Medilink UK Business Awards in Outstanding Achievement category...more
24/03/2017 Business Development Executive required at Xenogesis - Ends 28/04/2017...more
15/12/2016 XenoGesis opens state-of-the-art Bioanalysis Suite...more
08/11/2016 XenoGesis Celebrates 5th Anniversary...more
21/10/2016 XenoGesis Newsletter: Website, US Expansion, Erasmaus, 5th Birthday...more
29/09/2016 XenoGesis Invests in Agilent AriaMx Real-Time PCR System...more
28/09/2016 Xenogesis Adds CYP Induction And Gene Expression Assays To Its Portfolio...more
16/09/2016 XenoGesis Teams Up With Juniper Pharma Services For BOS London 2016...more
09/09/2016 XenoGesis Has Appointed Sabrina Mogle to Spearhead US Business Development Strategy...more
26/08/2016 XenoGesis joins the BioPartner programme...more
